Johnson & Johnson’s MedTech Segment Shines with Impressive Q3 Growth
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19.
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
Johnson & Johnson (NYSE: JNJ) reported a robust performance in the third quarter of 2024, demonstrating a 5.2% increase in reported sales, reaching $22.5 billion. The operational growth was slightly higher at 6.3%, showcasing the company’s resilience and adaptability in a competitive market.
This growth was driven by strategic advancements in both the Innovative Medicine and MedTech segments. In particular, the MedTech segment saw a 5.8% increase in reported sales, bolstered by the performance of electrophysiology products and the launch of new technologies such as the VELYS Spine and Shockwave E IVL Catheter.
The Innovative Medicine segment also contributed significantly, with worldwide operational sales growing by 6.3%. This growth was largely fueled by the success of products like DARZALEX in the oncology sector and TREMFYA in immunology.
However, the segment faced some challenges, with products like STELARA and SIMPONI experiencing a decline in sales. Despite these hurdles, the segment’s performance underscores Johnson & Johnson’s commitment to delivering innovative healthcare solutions.
Earnings per share (EPS) for the quarter were reported at $1.11, a decrease of 34.3% from the previous year, primarily due to one-time special charges and acquired in-process research and development (IPR&D) expenses.
On an adjusted basis, EPS was $2.42, marking a 9.0% decline. The company’s free cash flow year-to-date stood at approximately $14 billion, reflecting strong cash generation capabilities despite the challenges faced.
Johnson & Johnson Reports Double Beat in Third Quarter
Johnson & Johnson’s third-quarter performance, while strong in several areas, fell short of market expectations. Analysts had anticipated an EPS of $2.19 and revenue of $22.17 billion. The reported EPS of $1.11 was significantly below expectations, largely due to the aforementioned special charges and IPR&D expenses.
However, the adjusted EPS of $2.42 exceeded expectations, indicating robust underlying business performance when excluding these one-time items. Revenue, on the other hand, surpassed expectations, coming in at $22.5 billion compared to the anticipated $22.17 billion. This revenue beat was driven by solid sales in both the U.S. and international markets.
In the U.S., sales grew by 7.6%, reflecting strong demand for the company’s innovative products. International sales also saw a modest increase, despite facing headwinds from currency fluctuations.The company’s performance in the MedTech segment was particularly noteworthy, with operational sales growth of 6.4%, exceeding the expectations set for this segment.
This growth was supported by strategic acquisitions and the successful integration of new technologies, which helped offset declines in other areas. Overall, while the EPS fell short of expectations, the revenue beat and segmental growth highlight Johnson & Johnson’s robust operational capabilities.
Johnson & Johnson Revises Full Year Guidance, Expects $9.91 Adjusted Operational EPS
Looking ahead, Johnson & Johnson has updated its full-year 2024 guidance, reflecting both improved performance and the impact of recent acquisitions. The company now expects adjusted operational EPS to be around $9.91, down from the previous guidance of $10.05. This revision accounts for the costs associated with the acquisition of V-Wave, which more than offset the performance improvements observed during the quarter.
The company’s operational sales guidance has been adjusted to a range of $89.4 billion to $89.8 billion, with a midpoint of $89.6 billion. This reflects an expected growth rate of 6.3% to 6.8% compared to the prior year.
Johnson & Johnson’s leadership remains optimistic about the company’s long-term growth prospects, driven by its strong pipeline and strategic investments in innovative healthcare solutions.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
